We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
+49.54%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$566M
Cap. Flow
+$243M
Cap. Flow %
18.34%
Top 10 Hldgs %
65.15%
Holding
66
New
12
Increased
17
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$45.8M
2
QTTB icon
Q32 Bio
QTTB
+$26.3M
3
CAPR icon
Capricor Therapeutics
CAPR
+$24.4M
4
CELC icon
Celcuity
CELC
+$22.1M
5
QURE icon
uniQure
QURE
+$22M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$19.8M
2
SLNO
Soleno Therapeutics
SLNO
+$6.7M
3
ALLO icon
Allogene Therapeutics
ALLO
+$2.69M
4
KALV
KalVista Pharmaceuticals
KALV
+$411K

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Consumer Staples 0.22%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
26
Apogee Therapeutics
APGE
$10.2B
$9.29M 0.7%
70,000
– –
SYRE icon
27
Spyre Therapeutics
SYRE
$7.97B
$8.88M 0.67%
+100,000
New +$7.3M
COGT icon
28
Cogent Biosciences
COGT
$6.02B
$8.71M 0.66%
225,000
– –
CYTK icon
29
Cytokinetics
CYTK
$10B
$8.52M 0.64%
100,000
– –
RLAY icon
30
Relay Therapeutics
RLAY
$4.11B
$8.42M 0.63%
+450,000
New +$6.53M
CBIO
31
Crescent Biopharma
CBIO
$659M
$8.17M 0.62%
453,686
– –
CTNM
32
Contineum Therapeutics
CTNM
$641M
$8.1M 0.61%
494,000
– –
KZIA
33
Kazia Therapeutics
KZIA
$155M
$7.88M 0.59%
+560,000
New +$6.82M
STTK icon
34
Shattuck Labs
STTK
$707M
$6.94M 0.52%
+1,000,000
New +$6.24M
AVTX icon
35
Avalo Therapeutics
AVTX
$1.05B
$6.93M 0.52%
375,000
+75,000
+25% +$1.19M
FBRX
36
DELISTED
Forte Biosciences
FBRX
$5.83M 0.44%
+274,500
New +$6.51M
RLMD icon
37
Relmada Therapeutics
RLMD
$462M
$5.83M 0.44%
842,106
– –
MLTX icon
38
MoonLake Immunotherapeutics
MLTX
$1.28B
$5.35M 0.4%
275,000
– –
ZURA icon
39
Zura Bio
ZURA
$548M
$5.31M 0.4%
900,000
– –
HELP
40
Cybin Inc
HELP
$890M
$5.22M 0.39%
790,000
+150,000
+23% +$750K
ODTX
41
Odyssey Therapeutics
ODTX
$1.17B
$5.15M 0.39%
+275,000
New +$4.82M
IMTX icon
42
Immatics
IMTX
$1.44B
$4.81M 0.36%
+475,000
New +$5.02M
FTH
43
Faeth Therapeutics
FTH
$874M
$4.51M 0.34%
+180,505
New +$4.17M
GPCR icon
44
Structure Therapeutics
GPCR
$3.38B
$4.03M 0.3%
75,000
– –
ORIC icon
45
Oric Pharmaceuticals
ORIC
$1.37B
$3.79M 0.29%
350,000
+173,500
+98% +$1.57M
ANTX icon
46
AN2 Therapeutics
ANTX
$211M
$3.63M 0.27%
749,035
– –
NMRA icon
47
Neumora Therapeutics
NMRA
$261M
$3.4M 0.26%
+2,000,000
New +$3.81M
INO icon
48
Inovio Pharmaceuticals
INO
$133M
$3.13M 0.24%
2,844,994
+474,872
+20% +$563K
ALLO icon
49
Allogene Therapeutics
ALLO
$698M
$3.12M 0.24%
1,500,000
-1,225,000
-45% -$2.69M
SLDB icon
50
Solid Biosciences
SLDB
$1.05B
$3M 0.23%
300,000
– –
1
2
3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Boxer Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Boxer Capital Management held 66 positions worth $1.33B, up 74% from $762M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Boxer Capital Management deployed $243M of net new capital in Q2 2026, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Q32 Bio: 3,149,310 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Miscellaneous.

On the sell side, the largest reduction was Allogene Therapeutics, an estimated $2.69M trimmed.

  • Boxer Capital Management's largest Q2 2026 buy was Q32 Bio: 3,149,310 shares worth $40.1M.
  • Boxer Capital Management added most to Abivax in Q2 2026, an estimated $45.8M increase.
  • Boxer Capital Management's biggest Q2 2026 reduction was Allogene Therapeutics, cutting an estimated $2.69M.
  • Boxer Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Boxer Capital Management's ten largest holdings make up 65% of its $1.33B portfolio in Q2 2026.
  • Boxer Capital Management opened 12 new positions and closed 3 in Q2 2026.
  • Boxer Capital Management's portfolio value rose 74% quarter-over-quarter to $1.33B.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.